Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition  

作　　者：Shen Zhang Bin-Yan Zhong Lei Zhang Wan-Sheng Wang Cai-Fang Ni 

机构地区：[1]Department of Interventional Radiology,The First Affiliated Hospital of Soochow University,Suzhou 215006,Jiangsu Province,China

出　　处：《World Journal of Gastrointestinal Surgery》2022年第6期528-537,共10页世界胃肠外科杂志（英文版）（电子版）

基　　金：Supported by the National Natural Science Foundation of China;No. 81901847;Natural Science Foundation of Jiangsu Province;No. BK20190177;the Suzhou Science and Technology Youth Plan;No. KJXW2018003

摘　　要：Multi-session transarterial chemoembolization(TACE)is usually needed for the treatment of intermediate-stage hepatocellular carcinoma(HCC),but it may not always have a positive influence on prognosis due to high heterogeneity of HCC.To avoid ineffective repeated TACE,the concept of TACE failure/refractoriness has been proposed by several organizations and is being addressed using tyrosine kinase inhibitors.The concept of TACE failure/refractoriness is controversial due to ambiguous definitions and low evidence-based data.To date,only a few studies have examined the rationality concerning the definition of TACE failure/refractoriness,although the concept has been introduced and applied in many TACE-related clinical trials.This review focuses on some of the issues related to different versions of TACE failure/refractoriness,the rationality of related definitions,and the feasibility of continuing TACE after so-called failure/refractoriness based on published evidence.A suggestion to re-define TAEC failure/refractoriness is also put forward.

关 键 词：Hepatocellular carcinoma Transarterial chemoembolization FAILURE REFRACTORINESS 

分 类 号：R735.7[医药卫生—肿瘤]